Bausch Health : Announces 2020 Annual Meeting Of Shareholder Results
April 29, 2020 at 04:50 pm EDT
Share
LAVAL, Quebec, April 29, 2020 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced the election of the eleven directors nominated at its 2020 annual meeting of shareholders held on April 28, 2020. The detailed results of the vote for the election of directors are set out below:
Name
For
Withheld
Broker Non-Votes
Richard U. De Schutter
216,315,704
5,259,134
59,178,282
D. Robert Hale
211,714,041
9,860,797
59,178,282
Dr. Argeris (Jerry) N. Karabelas
215,596,446
5,978,392
59,178,282
Sarah B. Kavanagh
217,011,297
4,563,541
59,178,282
Joseph C. Papa
212,494,697
9,080,141
59,178,282
John A. Paulson
219,853,068
1,721,770
59,178,282
Robert N. Power
208,740,697
12,834,141
59,178,282
Russel C. Robertson
215,372,886
6,201,952
59,178,282
Thomas W. Ross, Sr.
215,468,972
6,105,866
59,178,282
Andrew C. von Eschenbach, M.D.
219,493,913
2,080,925
59,178,282
Amy B. Wechsler, M.D.
216,271,318
5,303,520
59,178,282
At the annual meeting of shareholders, shareholders also approved in a non-binding advisory vote the compensation of the Company's named executive officers, an amendment to the Company's Amended and Restated 2014 Omnibus Incentive Plan to increase the number of common shares, no par value, of the Company authorized under such plan, and appointed PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the Company's 2021 annual meeting of shareholders.
The final vote tabulation on all matters voted on at the meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's website at www.bauschhealth.com.
About Bausch Health Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.
Investor Contact:
Media Contact:
Arthur Shannon
Lainie Keller
arthur.shannon@bauschhealth.com
lainie.keller@bauschhealth.com
(514) 856-3855
(908) 927-1198
View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch-health-announces-2020-annual-meeting-of-shareholder-results-301049711.html
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.